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Recom mendations for Drug Allocation, Tuberculosis Prevention, and 
Patient Care During Isoniazid Shortages
Summary: Shortages of isoniazid (INH), a cornerstone drug for treating tuberculosis disease (TB) and 
latent Mycobacterium tuberculosis infection (LTBI), are continuing. This notice gives an update on the 
shortages and expands general guidance to public health officials and clinicians about how to adjust 
practices in response to the shortages from that outlined in CDC ’s December 21, 2012, Morbidity and 
Mortality Weekly Report (MMWR) (http://www.cdc.aov/mmwr/Dreview/mmwrhtml/mm6150a4.htm). It also 
outlines national plans for restoring INH supplies and lists published guidance that could assist in making 
treatment decisions when INH is unavailable.
Background
U.S. INH production has been interrupted, and stocks are dwindling. Consequent to the critical shortage 
of 300 mg tablets that was recently reported (1), the stocks of 100 mg tablets in some localities are 
reportedly being depleted. An initial forecast date for restoring INH production has been extended from 
late January 2013 to as late as March 2013 (1,2); however, the forecasts are unstable and vary by 
company. One of three pharmaceutical companies supplying INH, VersaPharm Incorporated, Marietta, 
Georgia, has notified public health officials that it is cancelling all INH backorders and not accepting new 
orders.
Clinical and Public Health Recommendations
While INH is in shortage, clinicians should coordinate TB and LTBI treatment plans with their jurisdictional 
public health officials, who should set priorities for allocating INH stock locally. These priorities should be 
set according to the immediate medical needs of individual patients and a general TB control strategy:
1) treating patients who have TB disease,
2) treating LTBI patients who are diagnosed during contact tracing of contagious TB (i.e., 
contact investigations), and
3) treating LTBI patients who face the greatest likelihood of TB disease (e.g., HIV-infected 
patients) or the hazard of severe illness (e.g., children <5 years old).
Treatment for LTBI can be postponed when the likelihood or hazard of TB disease is low, but systems 
should be developed for recalling patients when INH becomes available.
The World Health Organization (WHO) recommends that “drugs for the full course of treatment are 
reserved for the patient at the outset of treatment” (3). However, the abrupt onset of the INH shortage 
means that treatment for some TB patients could be disrupted in mid-course. Decisions for continuing 
treatment in these situations should be made on a case-by-case basis in consultation with a TB expert, as 
arranged by jurisdictional public health officials.
Fixed dose combination formulations of INH and rifampin or INH, rifampin, and pyrazinamide can be used 
for treating TB disease if the dosages of all the drugs are correct for the patient (4). However, at least one 
fixed dose combination is already on backorder, and stocks are believed to be depleted. A full treatment 
course of drugs should be secured before starting treatment with one of these combinations.
Regimens without INH for treating TB disease are less well studied than those with INH. CDC, the 
American Thoracic Society, and the Infectious Diseases Society of America have recommended a 
regimen of rifampin, pyrazinamide, and ethambutol for 6 months, with consideration of a fluoroquinolone, 
such as moxifloxacin or levofloxacin, for more extensive disease, when the infecting M. tuberculosis 
isolate is INH-resistant or the patient is intolerant of INH (4). Directly observed therapy should be used for 
reducing the potential for acquired rifampin resistance.
An alternative treatment regimen for LTBI, when the infecting M. tuberculosis is believed to be INH 
resistant, or when the patient cannot tolerate INH, is rifampin administered for 4 months, either self­
administered or directly observed (5). This regimen has been adopted for routine use by some U.S. TB 
program directors. A combination regimen of INH and rifampin for 3 or 4 months is used overseas and in 
some U.S. jurisdictions, although it is not currently recommended in U.S. national guidelines (5,6). This 
regimen could be prescribed via a fixed dose combination of INH and rifampin if supplies for complete 
treatment courses are in stock. The combination regimen of rifampin and pyrazinamide for 2 months is 
not recommended because of excess toxicity. Any of the alternative regimens for TB disease or LTBI 
could be more expensive than the standard regimens.
CDC is working with the Food and Drug Administration (FDA), the National Tuberculosis Controllers 
Association, and the two pharmaceutical companies currently planning to supply INH (Teva 
Pharmaceuticals USA, Sellersville, Pennsylvania; and Sandoz Inc., Princeton, New Jersey) to determine 
current INH stocks, jurisdictions with urgent needs, and options for restoring supplies as soon as can be 
safely done. CDC will monitor notifications from public health officials of INH shortages and stocks, and 
will provide updates as they are available on the website for the Division of Tuberculosis Elimination at 
http://www.cdc.gov/tb/.
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